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Abstract 
Evans blue (EB) dye has owned a long history as a biological dye and diagnostic 
agent since its first staining application by Herbert McLean Evans in 1914. Due to its 
high water solubility and slow excretion, as well as its tightly binding to serum 
albumin, EB has been widely used in biomedicine, including its use in estimating 
blood volume and vascular permeability, detecting lymph nodes, and localizing the 
tumor lesions. Recently, a series of EB derivatives have been labeled with PET 
isotopes and can be used as theranostics with a broad potential due to their improved 
half-life in the blood and reduced release. Some of EB derivatives have even been 
used in translational applications in clinics. In addition, a novel necrosis-avid feature 
of EB has recently been reported in some preclinical animal studies. Given all these 
interesting and important advances in EB study, a comprehensive revisiting of EB has 
been made in its biomedical applications in the review. 
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Introduction 
Dating back to the early twentieth-century, lots of blue dyes were synthesized like 
Methylene blue, Patent blue and Trypan blue, etc, and a comparison of main blue dyes 
was given in Table 1 [1-4]. Among those, Evans blue (EB) dye is just one that has a 
long history as a biological dye and clinical diagnostic agent [5]. As a synthetic 
bis-azo dye , EB dye also named T-1824 and Direct Blue 53. Differently, with the first 
staining application initiated by Herbert McLean Evans in 1914, this dye became 
famous when sold by the Eastman Kodak Company under the name of “Evans blue” 
in recognition of Mr. Evan’s contributions to the development and use of dyes since 
1936 [5, 6]. From that moment, the name “Evans blue” was widely accepted. 
EB dye, with a molecular weight of 961 Da and high water solubility (280g/l), 
strongly binds to serum albumin in vivo and in vitro, and, thereby, becomes a high 
molecular weight protein tracer (69 kDa) [7-10]. When injected intravenously or 
intraperitoneally, albumin-bound EB remains stable in the blood and distributes 
throughout the entire body. Once injected in excess, EB dye can stain an entire animal 
including eyes, ears, nose, and paws with an intense blue color [11, 12].  
In addition, Steinwall and Klatzo in 1966 reported that EB dye can emit a bright 
red fluorescence when activated with green light [7]. Thus, the dye provides a simple 
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and convenient way of identification both macroscopically and microscopically using 
fluorescence for both morphological investigation and quantification. The fluorescent 
feature of EB dye has been used in various aspects including the characterization of 
the lymph nodes which drain the liver [13], confirmation of a satisfactory injection 
into the heart chambers of a zebrafish embryo [14], and observation of the 
extravasation of the dye from blood vessels into tissues [15-17].  
Due to its high water solubility and slow excretion, as well as its firmly binding 
to serum albumin, EB is also widely used in biomedicine including the estimation of 
blood volume, the assessment of vascular permeability to macromolecules, the 
detection of lymph nodes, and the location of the tumor lesions [12, 18-24].  
More recently, a series of EB derivatives have been labeled with PET isotopes 
and can be used as theranostics with broad potential applications [25, 26]. EB also has 
a necrosis-avid feature as EB-bound albumin preferentially enters damaged cells, but 
not healthy cells, and persists within the damaged cells [14]. Thus, EB can be used as 
an agent for tissue viability assessment. This article reviews the features of EB and its 
potential applications in biomedicine. 
Applications derived from albumin-binding characteristic of Evans Blue dye  
The strong binding capacity of EB dye to serum albumin has been demonstrated 
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and this property has become widely accepted [7, 8, 10]. Tsopelas et al investigated a 
series of 20 sulfonic acid dyes in 2002 and elaborated that protein binding ability was 
correlated with dye molecular structure. He demonstrated that the EB dye with 
tetrasulfonic acid group yielded 70% protein binding affinities（Table 1）[27]. 
Moreover, sulfonation reaction between sulfonic acid group of dye and amino group 
on protein surface was responsible for the dye-protein binding mechanism.  
In various species, the binding capacity of albumin appears to be strongest in 
humans and dogs as 8-14 moles of Evans blue [28]. When injected intravenously , EB 
becomes fully albumin-bound and only a small proportion of free EB (0.11%-0.31%) 
can be found in the blood. The fact that EB dye is confined to the blood makes it 
unique among other dyes, e.g., sodium fluorescein, which evenly distributes between 
the blood and organs such as the liver [10].  
EB is eliminated from the circulating blood by the liver but not kidneys over time, 
which avoids the coloration of urine [27]. Wolman et al [8] briefly reported the 
gradual disappearance of EB from the plasma and found that the EB in the plasma 
dropped rapidly over 24h and remained very low in the blood after 3 days and was 
hardly detectable in their experiments. Importantly, as its unique characteristic, 
EB-protein complex with a high molecular weight may prevent its passage into living 
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cells or across the blood-brain barrier. This leads to a variety of clinical applications 
which will be elaborated later in this article [29-31].    
Use of Evans Blue dye for estimation of blood volume 
The evaluation of changes in total blood volume is an interesting topic. The use 
of EB dye for this purpose was introduced by Keith et al in 1915 [28, 32]. Earlier 
researchers in the field used red dyes from this class such as vital red, new vital red, 
and Congo Red. Until 1920, EB dye was considered superior to all the red dyes based 
on the investigations of Dawson et al, whose working principle of EB dye is now 
briefly described [33].  
When a known quantity of dye (N) is injected into the blood stream, after an 
interval required for complete mixing, the quantity of dye (n) in 1 ml of withdrawn 
blood sample is analyzed. According to the relationship V = N/n, the plasma volume 
(V) can be calculated [34]. Then the total blood volume can be correctly calculated 
from the plasma volume according to the value of the hematocrit. Clearly, the only 
measurement that can be influenced by vital processes is that of n.  
The dye dilution method using EB dye to measure plasma volume was gained 
wide acceptance in the middle of the twentieth century [35]. A wide variety of 
improvements and extraction methods were studied by researchers from various 
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countries [32, 36-40]. To date, quantitation of EB dye can be optimized in limited 
tissue samples as much as 30 l [41]. However, since radioisotopic method to 
measure plasma volume was first introduced by Gibson and his co-workers in 1946, it 
has gradually replaced the EB dye dilution method [34, 42]. Compared with the dye 
method (which occasionally overestimates the plasma volume), 131I-labeled protein 
has been confirmed as an accurate measurement of plasma volume in both dogs and 
human subjects [43]. However, the method has its shortcomings due to the prolonged 
stay of radiolabeled material in the body, e.g., repeated studies are not suggested on 
the same patient. Therefore, other methods such as trivalent chromium [51Cr(III)], 
hemoglobin-based oxygen carriers (HBOC), and carbon monoxide have been 
investigated as potential methods to estimate plasma volume [44, 45].  
The carbon monoxide method appeared promising, especially in critically ill 
patients [44]. Yet et al [45] developed a novel approach using HBOC in rabbits in 
2001, which is inexpensive and not time-consuming, while Baby et al [43] used 
51Cr(III) in rabbits in 2014 and found that it was easy and quick and could be 
performed repeatedly in the clinical setting as 51Cr(III) is not bound to albumin or red 
blood cells (RBCs). To some extent, the Evans blue dye method to measure plasma 
and blood volumes is limited in animals, but in humans, 51Cr(III) and HBOC are more 
promising for future clinical applications [46]. 
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Use of Evans Blue dye for determination of cardiac output 
The measurement of cardiac output by the dye injection method was established 
by Stewart [47] and later modified by Hamilton [48]. Evans blue dye, as a vital stain, 
had been widely used in this aspect and the validity of the EB dye-injection method 
has been shown to correlate well with the Fick procedure under different experimental 
conditions in dogs and humans [48, 49]. However, because of the slow excretion and 
undesirable discoloration, the EB dye was limited when repeated injections in patients 
were required. By contrast, Lacy et al [19] demonstrated indigo carmine as an 
alternative to EB due to its firmly binding to albumin and rapid removal by the liver 
and kidneys in 1955. In addition, Davis et al [1] investigated a series of blue dyes in 
1958 and found three rapid bloodstream clearance rates of dyes suitable for frequent 
serial estimation of the cardiac output. These included Patent Blue A, Brilliant Blue, 
and Patent Blue V. However, owing to the invasiveness of the Fick technique and the 
dye injection method, they have been replaced by other more modern and simplified 
techniques including thermodilution techniques, lithium dilution, bioreactance and 
Doppler technique or echocardiography [50, 51]. A few detailed reviews on this topic 
can be referred [50-52]. Therefore, EB and other blue dyes are no longer suitable for 
the determination of cardiac output except used as a reference. 
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Use of blood pool effect of Evans Blue dye 
EB dye is a permeable dye that can be easily taken up by degenerated or damaged 
cells but not taken up by cells with an intact membrane [14]. However, interestingly, 
EB dye and triphenyl tetrazolium chloride (TTC) ex vivo double-staining are usually 
used together to assess the infarct size in acute myocardial infarction in both canine 
and murine models, where EB is delivered to the coronary arteries and TTC is applied 
to stain the surface of cardiac sections [45, 53-57]. When perfused into the aorta and 
coronary arteries in a retrograde manner, EB dye can uniformly distribute to 
everywhere in the vascular bed of normal myocardium, while infarcted myocardium 
or areas at risk cannot be stained due to the occlusion of the affected coronary arterial 
branch. The rationale behind TTC staining is that infarcted myocardium has lost 
dehydrogenase so that the colorless dead tissue on TTC cannot be converted to a red 
formazan [58]. Thus, the nonischemic area is stained blue, while the viable 
myocardium in the area at risk is stained red, and the infarcted myocardium appears 
pale [45].  
EB dye can also be used alone to delineate which region of myocardium is 
perfused or hypoperfused based on accessibility to the dye [56]. But it seems to be 
paradoxical that the EB–perfused area, which is not at risk, is totally different from 
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EB–stained cardiomyocytes that experience injury [59]. Indeed, due to the blood pool 
effect of EB, when perfused ex vivo, the EB–perfused area can stain rapidly following 
the branches of coronary artery. In contrast, the EB–staining of necrotic 
cardiomyocytes is due to the dye’s affinity for dead cells, which will be addressed. 
Therefore, it is rational to say that EB dye could have a dual-function, i.e.,  
assessment of the myocardial area at risk and assessment of infarcted myocardium. 
Use of Evans Blue dye for assessment of vascular permeability 
Integration of selective permeable barriers is vital for proper organ functioning 
and the maintenance of homeostasis. Such barriers include the endothelial cell barrier 
of blood vessels, the blood-brain barrier (BBB), the blood–retinal barrier, the 
blood-spinal cord barrier, and the blood-placental barrier [60]. The majority of 
selective permeable barriers are constituted primarily of tight junctions between 
endothelial cells to maintain barrier integrity. Under physiologic conditions, selective 
permeable barriers permit a selective transport of micromolecular substances but are 
impermeable to macromolecules such as albumin [61]. Thus, the EB dye, which 
strongly binds to albumin, remains restricted within the blood circulation and cannot 
cross the barrier. When various diseases result in a disruption of the barrier and 
increased vascular permeability, EB-bounded albumin may extravasate from the 
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circulation into neighboring tissues. Leak of dye across the BBB or blood vessel 
signifies a disintegration of the barrier, and the accumulation of EB dye can be 
quantified after extraction from the stained tissue. The advantage of using EB dye as a 
tracer is its ability to be identified macroscopically which gives a gross indication of 
its distribution. Furthermore, the extravasated EB dye within tissue can be observed 
by red fluorescence in tissue sections by fluorescence microscopy and quantified by 
colorimetry, spectrophotometry, and spectrophotofluorometry [60, 62, 63]. Thus, EB 
dye is extensively used to assess vascular permeability and BBB permeability 
described in various models, such as the classical Miles assay [24, 64, 65], the 
endothelial damage model caused by trauma [66], the stroke model [67], the cerebral 
ischemic model [62], and the breast cancer brain metastasis model [30].   
In addition, Soubeyrand et al [68] and Pettersson et al [69] used EB dye to 
measure the permeability of the blood-spinal cord barrier and Xu et al [70] detected 
the blood–retinal barrier breakdown by quantification using EB. It is worthy of noting 
that the stain administration route by intraperitoneal and intravenous injection had no 
difference on the amount of EB dye stain accumulated but a strong time-dependent 
tendency towards increase in stain accumulation [71]. As a rapid and inexpensive 
method, EB dye is still the most commonly used marker of brain barrier integrity and 
vascular permeability, however, its associated problems of tissue discoloration and 
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potential toxicity need to be considered. 
Use of Evans Blue dye for detection of lymph nodes 
Visualization of the lymphatic system plays a significant role in assessing various 
malignancies and immune responses to foreign antigens in humans and in animal 
models [23]. The use of EB dye has become a major method for mapping lymphatic 
drainage. Due to the conjugation of the dye to plasma proteins by sulfonation reaction, 
the complex is sufficiently large to be trapped inside the lymphatic lumen and 
transported along with lymphatic flow [27]. Upon subcutaneous administration, the 
dye is quickly taken up by the lymphatic vessels to the draining nodes. Once the 
lymphatic mapping is shown by the blue color of EB dye, subsequent sentinel node 
biopsy become possible, which is critical for studies of solid tumor metastasis and of 
regional immune responses following immunization [23, 72]. 
Due to this mechanism of action, Bobin et al [73] was able to evaluate the 
feasibility of sentinel lymph node identification in 100 breast cancer patients and 
confirmed the sensitivity of this technique (95%) in detecting nodal metastases. 
Harrell et al [23] accurately and rapidly identified lymph nodes and lymphatic 
drainage in the mouse by injecting the dye into the mouse footpad or tail. Zheng et al 
[13]successfully characterized the liver-draining lymph nodes by intrahepatic 
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injection. Similarly, Tervala et al [74] detected axillary lymph nodes and grafted 
lymph nodes by injecting EB dye solution intradermally. In addition, they analyzed 
the leakage into blood that were able to quantify lymphatic vessel function. 
Except the EB dye, several other dyes are useful for identification of sentinel 
lymph nodes and include Chicago sky blue, Patent blue, and Trypan blue [27, 75]. It 
was previously reported that when scintigraphy and EB dye are used in tandem, the 
false-negative rate for sentinel node localization is decreased compared with using 
either agent alone [75]. On the whole, EB dye is a promising method for the 
assessment of malignancy and lymphedema in humans and subsequent sentinel node 
biopsy, as well as the evaluation of lymphatic vessel function.  
Use of Evans Blue dye for the diagnosis and identification of tumors 
Most tumors are known to exhibit highly enhanced vascular permeability, which 
is considered to facilitate tumor growth and perhaps metastasis [15, 76]. Visual 
demarcation of tumor margins during operation will provide a greater accuracy in 
tumor resection. The use of a visible small molecular dye to address this challenge 
was suggested by Ozawa and Orringer [77]. EB dye is perfectly in accord with this 
demand, because EB dye may bind strongly to albumin, extravasates and remains for 
a prolonged time in the extravascular space due to the enhanced permeability and 
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retention (EPR) effect of tumors [78].   
Lots of articles using EB dye to demarcate tumor margins were published [30, 76, 
79, 80]. Prabhu [79] calculated the uptake of the dye within an intracranial tumor to 
determine the volume of tumor, and demonstrated that the method showed good 
correlation with the volume estimation from histological sections and 
gadolinium-enhanced magnetic resonance imaging. Likewise, a study by Elsen 
investigated the biodistribution of Evans blue in a normal rat bladder and a bladder 
carcinoma, and he found a significant difference of EB absorption between malignant 
tissues and normal bladder tissues after intravesical instillations [80]. Thus, the 
method of EB instillations combined with white-light cystoscopy could be a useful 
tool for diagnosing bladder cancer in clinical settings in future.  
Interestingly, by developing a liposomally nanoencapsulated Evans Blue dye 
(nano-EB), Roller [76] demonstrated that clearer tumor margins was demarcated with 
Nano-EB in an invasive tumor model compared with unencapsulated EB. This 
indicated that Nano-EB could deposited specifically to tumor tissue, which is 
normally considered the tumor-specific feature of the EB dye [76, 81].  
As we know, liposomal nanocarriers as drug carriers have been extensively 
investigated in nanomedicine, the special structure of liposomes can facilitate itself 
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evading the reticuloendothelial system and prolonging the circulation time in the 
bloodstream [82, 83]. Much effort has been made to design and optimize liposomal 
nanocarriers. For instance, incorporation of targeting moieties to tumors onto the 
liposomal may help to reduce the accumulation in non-target organs [83]. Therefore, 
Nano-EB may be used to provide accurate visual cues for the surgeon to 
intraoperatively delineate the tumor margins via two mechanisms, either via tumor 
EPR effect or via tumor-receptor targeting strategy [76]. 
In general, EB dye, especially liposomal nanocarriers encapsulated Evans blue, 
could be a useful agent to localize and demarcate the solid tumors more precisely due 
to its selective accumulation in the tumor site. This so-called tumor-specific feature 
may actually be attributed to the EPR effect which may be used to explain the 
mechanism of EB applications in many clinical settings.  
Use of Evans Blue dye as a necrosis-avid agent  
As we know, life and death are two forms of cellular existence. Cell death is an 
essential form in cell development. Cell death includes at least two independent 
modes, i.e., apoptosis and necrosis. EB dye was first reported by Gaff and 
Okong-O’Ogola as a vital stain for plant cells in 1971 [84]. In their study, EB dye 
leaked through damaged membranes and stained the dead cells, but was excluded by 
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viable cells.  
EB dye has been further investigated and used extensively for specifying cell 
death in microscopic studies [85]. Although EB dye has been shown to be reliable for 
the assessment of viability in plant cells, it remains unclear whether EB dye can be 
also used in mammalian cells. In 1995, Matsuda et al [86] attempted a new method 
using EB dye to identify degenerated muscle fibers in the mdx mouse and showed that 
EB-stained muscle fibers were either hypercontracted or degrading, which was 
consistent with the terminal-deoxynucleoitidyl transferase mediated nick end labeling
（TUNEL）positive myonuclei as supportive evidence for apoptosis. In contrast, a 
study by Straub et al in 1997 identified that muscular fibers showing EB dye staining 
under fluorescence microscopy was necrotic fibers [87]. Similarly, Miller et al [59] 
used EB dye to stain cardiomyocytes induced by myocardial contrast 
echocardiography in rats in 2007 and showed that the EB–stained cardiomyocytes had 
no TUNEL-positive nuclei after 24 h, which is evidence for necrosis instead of 
apoptosis. Klyen et al also confirmed that the area of EB dye accumulation was 
consistent with the necrotic myofibers shown on hematoxylin and eosin staining and 
optical coherence tomography images [88].  
Many researchers used EB dye to discriminate among injured cells in various 
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animal models, such as the zebrafish models of neuromuscular disease [14], mouse 
models of muscular dystrophy [89] and experimental injury and repair [90], rat 
models of stroke and cardiomyocyte injury [91], myocardial infarction core in a rabbit 
model [92] (Fig. 1), and reperfused partial liver infarction model in rats [93] ( Fig. 2).  
Furthermore, some studies have shown that EB’s derivatives, such as 
EB-DTPA-Gd, has a specific binding affinity to a vascular lesion with endothelial 
damage, which is independent of serum proteins or the blood stream. EB-DTPA-Gd 
was also found to have a high affinity for atherosclerotic plaques in vivo in ApoE–/– 
mice [94]. These findings implied the nature of necrosis-avidity for EB dye. Although 
the EB dye was considered as a necrosis-avid agent, the specific mechanism is still 
not clear [95]. 
 
Radiolabeled Evans Blue derivatives as theranostics 
In general, radiolabeling EB, such as in 99mTc-EB, scarcely alter the 
pharmacodynamic properties of EB itself. 99mTc-EB demonstrated that its affinity for 
plasma protein was not significantly different from that of nonlabeled EB and both 
agents had similar dynamics regarding the sentinel lymph node [27, 72]. With the 
advantages of both radioactive and color signals in a single dose, it appears to be 
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superior to the dual-injection technique of radiocolloid/blue dye in mapping the 
lymphatic system and discriminating sentinel lymph nodes [22, 96]. Therefore, 
99mTc-EB could be a promising agent in the clinical setting to guide sentinel node 
biopsy in various solid tumors in the near future.  
Taking full advantage of the albumin-binding feature of EB, Chen et al developed 
a number of radiolabeled EB derivatives [25, 26, 97-99]. These EB derivatives may 
be conjugated onto a therapeutic small molecule, peptide, or an oligonucleotide 
aptamer. Thus, they may be used as theranostics with a broad potential due to their 
improved half-life in the blood and reduced release. For instance, a version of 
truncated EB conjugated to 1,4,7-triazacyclononane-N,N’N’’-triacetic acid (NOTA) 
has been recently synthesized, named NEB. The NEB can be labelled with different 
PET isotopes including 18F-AlF, 64Cu, and 68Ga [97, 98]. These radiolabeled NEB 
derivatives were initially used as blood pool agents to evaluate myocardial infarction 
and vessel leakage in inflammation and tumors [97]. After local injection, the 
18F-AlF-NEB can be used to visualize and detect the sentinel lymph nodes with a high 
signal-to-noise ratio. More interestingly, as a blood-pool imaging agent and PET 
tracer, 68Ga-NEB has already had translational applications in clinics. A preliminary 
study showed the potential of 68Ga-NEB in differentiating hepatic hemangioma from 
other focal hepatic lesions [98]. 68Ga-NEB also outperformed conventional 99mTc-SC 
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lymphoscintigraphy in the evaluation of patients with different suspected lymphatic 
drainage abnormalities [99].  
When EB-malaimide, one of the truncated EB derivatives, was conjugated to 
anti-diabetic drug exendin-4 (denoted as Abextide), it showed great potential to treat 
type 2 diabetic mice due to the significantly extended biological half-life of Abextide 
through complexation with albumin in situ [25, 26]. This strategy provides 
possibilities for the development of long-acting therapeutic drugs for other small 
molecules and biologics [26]. 
 
Toxicity of Evans Blue dye  
EB dye has been widely used for different applications in the clinic and research, 
but few researchers have considered the probable toxicity of the dye. EB dye can 
cause delayed death in all mice at doses above 200 mg/kg body weight [100], but the 
usual dosage of 2% EB, 0.5 mL/kg (10mg/kg) or even lower causes much less toxicity 
compared to higher doses. In most cases, few reports of adverse reactions were seen. 
However, it was reported by Gibson and Gregersen in 1935 that pulmonary embolism 
was observed after intravenous injection of EB in rats. In 1974, Giger et al 
demonstrated that EB can cause platelet aggregation when the molar ratio of EB : 
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albumin is >1:1 [101]. Similarly, by the late end of the twentieth century, Moos and 
Mollgard found that free dye (albumin-unbound EB) in plasma caused 60% of 
neonatal and 20% of the adult animal deaths during their experiments, and the toxicity 
of free dye led to alteration of the BBB permeability, while it appeared to be safe 
when EB was used as single intravenous injection at a conventional clinical dose [101, 
102]. In addition, Jackiewicz et al also proved that EB dye caused a significant 
simplification of the junctional morphology in both normal and regenerating 
endothelium, which should be taken into account when using EB dye to assess various 
insults to blood vessels in 1998 [66]. Recently, an ex vivo experiment by Giansanti et 
al investigated the safety of EB dye. They found damage of ARPE-19 cells and RGC5 
cells with halogen and xenon light exposure should be a concern when the dye is used 
during vitrectomy [103]. The point that many researchers have easily ignored is that 
azo dyes, as a class, can potentially induce mutagenicity and carcinogenicity when 
split off or degraded into component aromatic amines, especially in the fetus. 
Although there is a lack of reports about the carcinogenicity of EB, it is necessary to 
consider the possibility when using EB in clinical practice. 
 
Conclusion 
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In summary, the once widely used EB dye dilution method has gradually been 
replaced by newer methods, such as radiolabeled albumin and radiolabeled red cells, 
for the estimation of blood volume and cardiac output. The blood pool effect of EB 
dye is limited when evaluating perfused or hypoperfused myocardium, but its utility 
in assessing vascular permeability and BBB integrity has increased. In addition, the 
use of radiolabeled EB and its derivatives will play an important role in clinical 
imaging of tumor lesions, evaluation of lymphatic disorders, and development of 
long-acting therapeutics. Importantly, the newly discovered necrosis-avid affinity of 
EB will facilitate the identification of necrotic tissues including myocardial infraction, 
cerebral stroke, degenerating muscular diseases, and even amyloidosis [104], and the 
assessment of therapeutic efficacy and prognosis of solid tumors. Although the 
mechanisms are still unclear and further investigation is required, EB dye as a vital 
stain has greatly contributed to biomedical research and may continue to benefit the 
development of medical practice and patient care. Therefore, the main advantage of 
new applications of Evans blue lies in its great potential use in clinical practice as 
mentioned above. 
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Fig. 1. Evaluation of myocardial infarction core (MI-core), area at risk (AAR) and 
salvageable zone (SZ) in a rabbit with reperfused MI by in vivo and ex vivo imaging 
techniques and dynamic imaging quantification [92].  
A: Delayed, enhanced cardiac magnetic resonance imaging displays the MI-core as a 
transmural hyperenhanced area involving anterior papillary muscle; B: T2-weighted 
imaging shows an extensive hyperintense region in the anterolateral wall; C: Digital 
radiograph of the red iodized oil-stained heart section shows a filling defect with few 
collateral vessels in the anterolateral wall in contrast to the rest of opaque left 
ventricle; D: photograph of the heart section stained by multifunctional staining 
depicts the MI-core as an Evans blue dye-stained blue lesion simulating what is seen 
in A and shows the normal ventricular wall in red leaving the AAR (including the blue 
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MI-core) unstained, which perfectly matches with the AAR in C, and whitish zones 
which are suggestive of the SZ; E: photomacroscopy of HE-stained heart slice views 
the MI-core as a hemorrhagic infarct similar in size to the blue lesion in F; F: 
photomicroscopy (×100) of HE-stained heart slice confirms the presence of the AAR 
(necrotic MI-core plus the viable but inflammatory SZ) and remote normal 
myocardium (NM) (reprinted and modified with permission from Feng Y, Chen F, Ma 
Z, Dekeyzer F, Yu J, Xie Y, Cona MM, Oyen R, Ni Y. Theranostics. 2013, 4:24-35). 
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Fig. 2. Postmortem analysis of necrotic and viable liver from rats with reperfused 
partial liver infarction who received iodine-123-labeled monoiodohypericin followed 
by the necrosis-avid dye, Evans blue [93].  
At 4, 24, and 48 hours (h) after radioactivity injection, liver necrosis is outlined by the 
Evans blue as a blue region (A1, B1, C1), with viable liver without staining (A1', B1', 
C1'). Autoradiograms of 50-μm-thick sections show higher tracer accumulation in the 
hepatic infarction (A2, B2, C2) than in viable liver (A2', B2', C2'). The color code bar 
represents the coding scheme for the radioactivity. On histologic sections, the 
presence of scattered liver necrosis (A3, B3, C3) and the location of the normal liver 
(A3', B3', C3') are confirmed (reprinted and modified with permission from Miranda 
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Cona M, Koole M, Feng Y, Liu Y, Verbruggen A, Oyen R, Ni Y. International Journal 
of Oncology 2014, 44: 819-829). 
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